Display options
Cite
Shecterle LM, Terry KR, St Cyr JA. Potential Clinical Benefits of D-ribose in Ischemic Cardiovascular Disease. Cureus. 2018;10(3):e2291doi: 10.7759/cureus.2291.
Shecterle, L. M., Terry, K. R., & St Cyr, J. A. (2018). Potential Clinical Benefits of D-ribose in Ischemic Cardiovascular Disease. Cureus, 10(3), e2291. https://doi.org/10.7759/cureus.2291
Shecterle, Linda M, et al. "Potential Clinical Benefits of D-ribose in Ischemic Cardiovascular Disease." Cureus vol. 10,3 (2018): e2291. doi: https://doi.org/10.7759/cureus.2291
Shecterle LM, Terry KR, St Cyr JA. Potential Clinical Benefits of D-ribose in Ischemic Cardiovascular Disease. Cureus. 2018 Mar 09;10(3):e2291. doi: 10.7759/cureus.2291. PMID: 29750132; PMCID: PMC5943027.
Copy Download .nbib Format: NLM
Share it on

Cureus. 2018 Mar 09;10(3):e2291. doi: 10.7759/cureus.2291.

Potential Clinical Benefits of D-ribose in Ischemic Cardiovascular Disease.

Cureus

Linda M Shecterle, Kathleen R Terry, John A St Cyr

Affiliations

  1. Research and Development, Jacqmar, Inc.

PMID: 29750132 PMCID: PMC5943027 DOI: 10.7759/cureus.2291

Abstract

Cardiovascular disease still remains the leading cause of deaths worldwide. Atherosclerosis, the most common type of cardiovascular disease, has continued to progress due to many factors, genetics, and lifestyles. All cells require adequate adenosine triphosphate (ATP) levels to maintain their integrity and function. Myocardial ischemia commonly found in atherosclerosis can produce lower levels of ATP, which affects not only cellular energy, but also alters normal function. D-ribose, a naturally occurring pentose carbohydrate, has been shown to increase cellular energy levels and improve function following ischemia in pre-clinical studies and have demonstrated potential benefits in clinical evaluations. This review paper presents an overview of ischemic cardiovascular disease and the potential role that D-ribose could play in improving myocardial energy levels and function in the area of ischemic cardiovascular diseases.

Keywords: adenine nucleotides; adenosine triphosphate; cardiology; cardiovascular disease; cardiovascular surgery; clinical benefits; d-ribose; pre-clinical and clinical trials

Conflict of interest statement

There have been 6 issued patents related to this technology

References

  1. Ther Adv Cardiovasc Dis. 2011 Aug;5(4):185-92 - PubMed
  2. J Cardiovasc Pharmacol Ther. 2000 Oct;5(4):249-58 - PubMed
  3. Cardiovasc Ultrasound. 2009 Feb 07;7:5 - PubMed
  4. Surgery. 1984 Aug;96(2):248-55 - PubMed
  5. Ther Adv Cardiovasc Dis. 2015 Jun;9(3):56-65 - PubMed
  6. Science. 1983 Apr 1;220(4592):81-2 - PubMed
  7. Circ Res. 2004 Jul 23;95(2):135-45 - PubMed
  8. Am J Physiol. 1979 Aug;237(2):H247-52 - PubMed
  9. Adv Exp Med Biol. 1986;194:401-14 - PubMed
  10. J Mol Cell Cardiol. 1981 Feb;13(2):229-39 - PubMed
  11. Cell Physiol Biochem. 2009;24(3-4):211-8 - PubMed
  12. Med Hypotheses. 1990 Jan;31(1):21-3 - PubMed
  13. JAMA. 2006 Nov 8;296(18):2209-16 - PubMed
  14. Lancet. 1992 Aug 29;340(8818):507-10 - PubMed
  15. Med Hypotheses. 2003 Feb;60(2):149-51 - PubMed
  16. Pflugers Arch. 1978 Sep 29;376(3):223-7 - PubMed
  17. J Thorac Cardiovasc Surg. 1982 Mar;83(3):390-8 - PubMed
  18. J Surg Res. 1989 Feb;46(2):157-62 - PubMed
  19. J Nucl Med. 1991 Feb;32(2):193-200 - PubMed
  20. Basic Res Cardiol. 1989 May-Jun;84(3):332-43 - PubMed
  21. J Mol Cell Cardiol. 1984 Sep;16(9):863-6 - PubMed
  22. J Am Coll Cardiol. 1991 Dec;18(7):1671-81 - PubMed
  23. Eur J Heart Fail. 2003 Oct;5(5):615-9 - PubMed
  24. Eur Heart J. 2003 Feb;24(4):320-8 - PubMed
  25. J Thorac Cardiovasc Surg. 1989 May;97(5):771-8 - PubMed
  26. JAMA. 2003 Jan 8;289(2):194-202 - PubMed

Publication Types